Background:

Enhanced CYP2D6 activity has been related to malignancies of the bladder, liver, pharynx, and stomach and, especially, to cigarette-smoking-induced lung cancer. The data suggests that enhanced CYP2D6-mediated metabolism of one or more dietary and other environmental agents, to form a reactive intermediate, plays a role in cancer initiation and/or promotion in various tissues. CYP2D6 polymorphism, which is responsible for the variation in metabolism of debrisoquine 4-hydroxylase, is important in the metabolism of more than 30 drugs and environmental chemicals, including as much as 20% of all commonly prescribed drugs.

Specificity:

CYP2D6 (A300) polyclonal antibody detects endogenous levels of CYP2D6 protein.

Alternative names:

Cytochrome P450 2D6; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; CYP2DL1

Species reactivity:

Human,Mouse,Rat

Host:

Rabbit

Ig type:

Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Immunogen:

Synthetic peptide, corresponding to amino acids 283-328 of Human CYP2D6.

Purification & Purity:

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Molecular weight:

~ 55 kDa

Applications:

WB IHC

Usage:

WB: 1:500~1:1000 IHC: 1:50~1:200

Storage:

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Precautions:

For research use only, not for use in diagnostic procedure.

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com